Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin to Prevent Chemotherapy-Induced Premature Ovarian Failure in Lymphoma
NCT01160315Phase 3Completed
- Sponsor
- Erasmus Hospital
- Start
- Jul 2002
- Primary completion
- Jun 2010
- Modality
- Peptides, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of triptorelin in primary ovarian insufficiency (POI) (2 arms), sponsored by Erasmus Hospital. Primary endpoint: Premature Ovarian Failure Rate at 5 years. Started Jul 2002; status: completed.
02
Drugs
triptorelin
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT01160315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01160315.